Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1281. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? (Abstract)

and proven efficacy.To compare the prevalences of PSA and colorectal cancer screening among US men.The 2001 Behavioral Risk Factor Surveillance System, an annual population-based telephone survey of US adults conducted by the Centers for Disease Control and Prevention, was used to gather data on a representative sample of men aged 40 years or older from all 50 states and the District of Columbia (n = 49 315).Proportions of men ever screened and up to date on screening for prostate cancer (with PSA (...) Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? The debate about the efficacy of prostate-specific antigen (PSA) screening for prostate cancer has received substantial attention in the medical literature and the media, but the extent to which men are actually screened is unknown. If practice were evidence-based, PSA screening would be less common among men than colorectal cancer screening, a preventive service of broad acceptance

2003 JAMA

1282. Colorectal cancer screening: scientific review. (Abstract)

testing can reduce colorectal cancer incidence and mortality. Case-control studies have shown that sigmoidoscopy is associated with a reduction in mortality, and observational studies suggest colonoscopy is effective as well. Combining fecal occult blood testing and sigmoidoscopy may decrease mortality and can increase diagnostic yield.The recommendation that all men and women aged 50 years or older undergo screening for colorectal cancer is supported by a large body of direct and indirect evidence (...) Colorectal cancer screening: scientific review. Screening for colorectal cancer clearly reduces colorectal cancer mortality, yet many eligible adults remain unscreened. Several screening tests are available, and various professional organizations have differing recommendations on which screening test to use. Clinicians are challenged to ensure that eligible patients undergo colorectal cancer screening and to guide patients in choosing what tests to receive.To critically assess the evidence

2003 JAMA

1283. Colorectal cancer screening: clinical applications. (Abstract)

Colorectal cancer screening: clinical applications. Screening for colorectal cancer reduces mortality in individuals aged 50 years or older. A number of screening tests, including fecal occult blood tests, sigmoidoscopy, double-contrast barium enema, and colonoscopy, are recommended by professional organizations for colorectal cancer screening, yet the rates of colorectal cancer screening remain low. Questions regarding the quality of evidence for each screening test, whether screening (...) for individuals at higher risk should be modified, the availability of the tests, and cost-effectiveness are addressed. Many potential barriers to colorectal cancer screening exist for the patient and the physician. Strategies to increase compliance for colorectal cancer screening are proposed.

2003 JAMA

1284. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61) Overview | Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | Guidance | NICE Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer Technology appraisal guidance [TA61] Published date: 27 May 2003 Share Save Guidance on capecitabine for treating metastatic colorectal cancer in adults. The recommendations originally

2003 National Institute for Health and Clinical Excellence - Technology Appraisals

1285. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. (Abstract)

to investigate methods for early detection of cancer. In our analysis, we compared fibre intake of 33971 participants who were sigmoidoscopy-negative for polyps, with 3591 cases with at least one histologically verified adenoma in the distal large bowel (ie, descending colon, sigmoid colon, or rectum). Odds ratios were estimated by logistic regression analysis.High intakes of dietary fibre were associated with a lower risk of colorectal adenoma, after adjustment for potential dietary and non-dietary risk (...) Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Although dietary fibre has been reported to have no association with colorectal adenoma and cancer, in some studies this topic remains controversial.We used a 137-item food frequency questionnaire to assess the relation of fibre intake and frequency of colorectal adenoma. The study was done within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a randomised controlled trial designed

2003 Lancet Controlled trial quality: uncertain

1286. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. Full Text available with Trip Pro

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. Colon cancers with high-frequency microsatellite instability have clinical and pathological features that distinguish them from microsatellite-stable tumors. We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer.Tumor specimens were collected (...) from patients with colon cancer who were enrolled in randomized trials of fluorouracil-based adjuvant chemotherapy. Microsatellite instability was assessed with the use of mononucleotide and dinucleotide markers.Of 570 tissue specimens, 95 (16.7 percent) exhibited high-frequency microsatellite instability. Among 287 patients who did not receive adjuvant therapy, those with tumors displaying high-frequency microsatellite instability had a better five-year rate of overall survival than patients

2003 NEJM Controlled trial quality: uncertain

1287. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. (Abstract)

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive (...) either 325 mg of aspirin per day or placebo. We determined the proportion of patients with adenomas, the number of recurrent adenomas, and the time to the development of adenoma between randomization and subsequent colonoscopic examinations. Relative risks were adjusted for age, sex, cancer stage, the number of colonoscopic examinations, and the time to a first colonoscopy. The study was terminated early by an independent data and safety monitoring board when statistically significant results were

2003 NEJM Controlled trial quality: predicted high

1288. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. (Abstract)

Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. The liver is the most frequent site for metastases of colorectal cancer, which is the second largest contributor to cancer deaths in Europe. We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients (...) with adenocarcinoma of the colon or rectum, with metastases confined to the liver.We randomly allocated 290 patients from 16 centres to receive either intravenous chemotherapy (folinic acid 200 mg/m2, fluorouracil bolus 400 mg2 and 22-h infusion 600 mg/m2, day 1 and 2, repeated every 14 days), or IHA chemotherapy designed to be equitoxic (folinic acid 200 mg/m2, fluorouracil 400 mg/m2 over 15 mins and 22-h infusion 1600 mg/m2, day 1 and 2, repeated every 14 days). The primary endpoint was overall survival

2003 Lancet Controlled trial quality: predicted high

1289. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. (Abstract)

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Policies of UK clinicians regarding the duration of chemotherapy for patients with advanced colorectal cancer are not consistent. We aimed to compare effectiveness of continuous and intermittent chemotherapy in such patients.Patients who responded or had stable disease after receiving 12 weeks of the regimens described by de Gramont and Lokich, or raltitrexed (...) indefinitely until disease progression. They showed that it is safe to stop chemotherapy after 12 weeks and re-start the same treatment on progression in patients with chemosensitive advanced colorectal cancer.

2003 Lancet Controlled trial quality: uncertain

1290. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation

Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation Ward (...) S, Kaltenthaler E, Cowen J, Brewer N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ward S, Kaltenthaler E, Cowen J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technology Assessment 2003; 7(32): 1-106

2003 Health Technology Assessment (HTA) Database.

1291. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer

condition and preferences of the individual. 1.3 The use of capecitabine or tegafur with uracil to treat metastatic colorectal cancer should be supervised by oncologists who specialise in colorectal cancer. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Antimetabolites, Antineoplastic /administration & Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Colorectal Neoplasms /drug therapy; Deoxycytidine /administration & Prodrugs /administration & Tegafur (...) Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database

2003 Health Technology Assessment (HTA) Database.

1292. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer

(92.8%). A total of 480 (32.6%) patients did not meet study eligibility criteria or were unavailable for analysis. Patients excluded were those enrolled in the HMO for less than a year before diagnosis, and those with a known history of colon polyps, ulcerative colitis, Crohns disease or familial polyposis syndrome. Also excluded were those patients whose cancer was detected following screening endoscopy or an FOBT performed in their physician's office. Study design This was a retrospective cohort (...) . Gastroenterology 2003; 125(6): 1645-1650 PubMedID Other publications of related interest Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-61. Ramsey SD, Berry K, Etzioni R. Lifetime cancer attributable cost of care for long term survivors of colorectal cancer. American Journal of Gastroenterology 2002;97:440-5. Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Colorectal Neoplasms

2003 NHS Economic Evaluation Database.

1293. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer Full Text available with Trip Pro

cancer. Genetics in Medicine 2003; 5(5): 353-336 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms, Hereditary Nonpolyposis /diagnosis; DNA Mutational Analysis /economics; Genetic Testing /economics; Humans; Microsatellite Repeats AccessionNumber 22003009942 Date bibliographic record published 30/11/2004 Date abstract record published 30/11/2004 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 (...) An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer Ramsey S D, Burke W, Clarke L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS

2003 NHS Economic Evaluation Database.

1294. Cost-effectiveness of colorectal cancer screening in the average risk population

critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for colorectal cancer (CRC) in those at average risk of the disease was studied. Six screening strategies were considered: no screening; one-time colonoscopic screening (COL); colonoscopy repeated at a 10-year interval (COL-10); annual faecal occult blood testing (FOBT); annual FOBT and flexible sigmoidoscopy in a 5-year interval (FOBT+SIG); and annual detection of altered human DNA in a stool (...) Cost-effectiveness of colorectal cancer screening in the average risk population Cost-effectiveness of colorectal cancer screening in the average risk population Cost-effectiveness of colorectal cancer screening in the average risk population Leshno M, Halpern Z, Arber N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed

2003 NHS Economic Evaluation Database.

1295. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis Full Text available with Trip Pro

colorectal carcinoma: a state-transition Monte Carlo decision analysis. Annals of Surgery 2003; 237(4): 544-555 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Aged; Colorectal Neoplasms /pathology; Cost-Benefit Analysis; Decision Support Techniques; Hepatectomy /economics; Humans; Liver Neoplasms /secondary /surgery; Male; Models, Statistical; Sensitivity and Specificity AccessionNumber 22003001367 Date bibliographic record published 28/02/2005 Date abstract record published 28/02 (...) Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis Gazelle G S, Hunink M G, Kuntz K M, McMahon P M, Halpern E F

2003 NHS Economic Evaluation Database.

1296. Potential impact of population-based colorectal cancer screening in Canada

colorectal cancer screening in Canada. Chronic Diseases in Canada 2003; 24(4): 81-88 PubMedID Other publications of related interest Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-77. Mandel JS, Bond JH, Church TR, et al. Reducing (...) mortality from colorectal cancer by screening for faecal occult blood. New England Journal of Medicine 1993;328:1365-71. Indexing Status Subject indexing assigned by NLM MeSH Aged; Canada /epidemiology; Colonoscopy; Colorectal Neoplasms /diagnosis /epidemiology /mortality; Cost-Benefit Analysis; Humans; Mass Screening /economics /methods /statistics & Middle Aged; Occult Blood; numerical data AccessionNumber 22004008773 Date bibliographic record published 31/10/2005 Date abstract record published 31/10

2003 NHS Economic Evaluation Database.

1297. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis

of colorectal cancer: a cost-effectiveness analysis. American Journal of Medicine 2003; 114(7): 546-554 PubMedID Other publications of related interest Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Annals of Internal Medicine 2001;135:769-81. Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Colonoscopy /economics /statistics & Colorectal Neoplasms /economics /pathology (...) Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis Ladabaum U, Scheiman J M, Fendrick A M Record Status This is a critical abstract of an economic evaluation that meets

2003 NHS Economic Evaluation Database.

1298. Screening for prostate, breast and colorectal cancer in renal transplant recipients

. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer: estimating the risks, benefits and cost. Annals of Internal Medicine 1997;126:468-79. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-61. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity and direct costs of colon, prostate and breast cancer care. Journal of the National (...) Cancer Institute 1995;87:417-26. Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms /diagnosis; Computer Simulation; Cost-Benefit Analysis; Female; Guidelines as Topic; Humans; Kidney Transplantation /adverse effects /standards; Male; Mass Screening /economics /methods; Prostatic Neoplasms /diagnosis; Time Factors AccessionNumber 22003000904 Date bibliographic record published 29/02/2004 Date abstract record published 29/02/2004 NHS Economic Evaluation Database (NHS EED

2003 NHS Economic Evaluation Database.

1299. Laparoscopic surgery for treatment of colon cancer</a>

-396. Franklin ME, Rosenthal D, et al. Prospective compairson of open vs. laparoscopic colon surgery for carcinoma. Dis Colon Rectum 1996; 39: 35-46. Fleshman JW, Nelson H, et al. Early results of laparoscopic surgery for colorectal cancer. Dis Colon Rectum 1996; 9:53-58. Wexner SD, Cohen SM. Port site metastases after laparoscopic colorectal surgery for cure of malignancy. Br J Surg 1995; 82:295-298. SBU Assessment presents a comprehensive, systematic assessment of available scientific evidence (...) Council on Technology Assessment in Health Care (SBU), the Medical Products Agency, the National Board of Health and Welfare, and the Federation of Swedish County Councils. References Lacy AM, Garcia-Valdecasas JC, et al. Short term outcome analysis of a randomized study comparing laparoscopic vs open colectomy for colon cancer. Surg Endosc 1995; 9:1101-1105. Stage JG, Schulze S, et al. Prospective randomized study of laparoscopic vs open colonic resection for adenocarcinoma. Br J Surg 1997; 84: 391

2003 Swedish Council on Technology Assessement

1300. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. (Abstract)

, we used immunohistochemistry with two different monoclonal antibodies, in-situ hybridisation, and PCR with DNA sequencing.Human cytomegalovirus proteins IE1-72 and pp65 were detected in a tumour cell-specific pattern in 14 (82%) of 17 and seven (78%) of nine colorectal polyps, respectively, and 12 (80%) of 15 and 11 (92%) of 12 adenocarcinomas, respectively, but not in adjacent non-neoplastic colon biopsy samples from the same patients (none of seven and none of two, respectively). Human (...) cytomegalovirus infection of colon-cancer cells (Caco-2) in vitro resulted in specific induction of Bcl-2 and cyclo-oxygenase-2 proteins, both of which are thought to contribute to progression of colon cancer.Human cytomegalovirus nucleic acids and proteins can be found that specifically localise to neoplastic cells in human colorectal polyps and adenocarcinomas, and virus infection can induce important oncogenic pathways in colon-cancer cells.

2002 Lancet